The views expressed on this podcast are those of the participants, not of Rogers News.

Yeah, it's a land grab.

And you can see that for two reasons.

First, like you said, typically when there's only two companies or even three companies,

they don't actually compete on a price.

They do lots of ad campaigns.

In America, you have tons and tons of commercials. And you actually, they may't actually compete on a price. They do lots of ad campaigns. In America,

you have tons and tons of commercials, and you actually, they may even raise prices. Because

they're all working together, you know, they don't actually admit it to the government because

that's an antitrust problem, but they don't actually, you know, they don't compete on price.

Here they are competing in price and also they are advertising extremely aggressively.

Weight loss drugs sold under the brands O OZempic and Mungaro, are available far and wide now.

The premise is relatively simple. You take a shot once a week and it's a colorless liquid that

basically goes into your body and wrestles your type 2 diabetes into submission

and in many cases leads to quite dramatic weight loss. There are two companies responsible for

making these drugs. It's Denmark's Nova Nordisk and in the US it's Eli Lilly and they've enjoyed

unprecedented success controlling this duopoly.

And there is so much hype about this market.

It is predicted by many analysts that revenue will reach over $100 billion by 20131.

But in the past year, that excitement has started to wane a little bit.

Tens of billions of dollars have been wiped off the value of Eli Lilly and Nova Nordisk.

And that's basically because they're having drug trials that may not have lived up to expectations.

...